Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 877 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Endocrine Clear all

Conditions: Lesions
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Advanced Breast Cancer
Interventions: Abemaciclib, Hydroxychloroquine 200 mg, Faslodex, Anastrazole, Letrozole, Hydroxychloroquine 400 mg, Hydroxychloroquine 600 mg; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prostatic Neoplasms
Interventions: Enzalutamide, NSAA, LHRHA or Surgical Castration; Drug
Lead sponsor: University of Sydney; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
Interventions: Computed Tomography, Dual X-ray Absorptiometry, Physical Examination, Quality-of-Life Assessment, Questionnaire Administration, Cabozantinib, Lenvatinib; Procedure · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes
Interventions: Islet cell transplantation; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation, Deleterious EPCAM Gene Mutation, Deleterious MLH1 Gene Mutation, Deleterious MSH2 Gene Mutation, Deleterious MSH6 Gene Mutation, Deleterious PALB2 Gene Mutation, Deleterious PMS2 Gene Mutation, Deleterious RAD51C Gene Mutation, Deleterious RAD51D Gene Mutation, Hereditary Breast and Ovarian Cancer Syndrome, Premenopausal
Interventions: Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Salpingectomy, Salpingo-Oophorectomy; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2041
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more

Conditions: Prediabetic State
Interventions: Oral glucose tolerance test; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Focus on Pain Regulation Mechanisms, Social Stress Mechanisms, Basic Affective Mechanisms, Attention Mechanisms, Brain Mechanisms, Immune Mechanisms, Endocrine Mechanisms
Interventions: Mindfulness Based Stress Reduction (MBSR), Health Enhancement Program (HEP); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Eribulin, Adriamycin, Cyclophosphamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: GlucoWatch® G2™ Biographer (GW2B), Continuous Glucose Monitoring System™ (CGMS); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 6
States / cities: Stanford, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Diabetes
Interventions: Intensive Diabetes Case Management; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HER2 Negative Breast Cancer
Interventions: Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy; Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: exemestane, adjuvant therapy, aromatase inhibition, conventional surgery, endocrine therapy, hormone therapy, neoadjuvant therapy, surgery; Drug · Procedure
Lead sponsor: Robert H. Lurie Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Islet Cell Transplantation, Type 1 Diabetes
Interventions: Islet cell transplantation; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma
Interventions: Best Practice, Biospecimen Collection, Dietary Intervention, Glucose Measurement, Magnetic Resonance Imaging, Monitoring, Questionnaire Administration, Supportive Care; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Breast Cancer
Interventions: gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, medical chart review, questionnaire administration; Genetic · Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetes Mellitus, Type 1
Interventions: Islet transplantation; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Thyroid Gland Medullary Carcinoma
Interventions: Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan, Neck Dissection, Surveillance, Thyroid Lobectomy, Thyroidectomy, Ultrasound Imaging; Procedure · Behavioral
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Pain, Pain, Chronic, Pain Syndrome, Pain, Neuropathic, Pain, Intractable
Interventions: Mindfulness Based Intervention; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet Transplantation and Bone Marrow; Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder, Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Sickle Cell Anemia in Children, Aplastic Anemia, Thalassemia in Children
Interventions: Vitamin D3, Standard Vitamin D3 Supplementation; Dietary Supplement
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 1 Year to 25 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes Mellitus, Type 2
Interventions: GEM + CGM; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 35 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Evaluation of Blood Vessel Formation in Endocrine Tumors

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Pancreatic Islet Cell Transplantation

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

The Effects of Mindfulness Training on Pain Regulation, Negative Affect, Attention, and Social Stress

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children

Intensive Case Diabetes Management (ICDM) to Prevent Readmission

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Biomarkers in Blood Samples From Older Breast Cancer Survivors

Islet Transplantation for Patients With Type 1 Diabetes

STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection

Investigating Biological Targets, Markers, and Intervention for Chronic Pain

Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus

A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT

The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication